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Rotterdam, The NetherlandsObjective. To improve the precision of the estimates of primary failure rates and primary and secondary 1 year patency of
radial-cephalic arteriovenous fistulas (RCAVF) for hemodialysis.
Design. Meta-analysis.
Materials and methods. A Medline search was performed of the English language medical literature between January
1970 and October 2002. Key words that were searched included radiocephalic fistula, arteriovenous shunt, Brescia-
Cimino fistula and patency. Primary failure, primary and secondary patency rates were analysed using the standard
mixed effects model, which allows for variability between the different studies.
Results. Eight prospective and 30 retrospective studies were included. The analysis showed a pooled estimated primary
failure rate of 15.3% (95% CI: 12.7–18.3%). In addition, the pooled estimated primary and secondary patency rates of
62.5% (95% CI: 54.0–70.3%) and 66.0% (95% CI: 58.2–73.0%), respectively, were calculated. Subgroup analysis
concerning various study characteristics, including study year, gender and age, did not reveal statistically significant
differences.
Conclusion. Although, the autogenous RCAVF is considered to be the primary choice for vascular access, this meta-analysis
indicates a high primary failure rate and only moderate patency rates at 1 year of follow-up.Keywords: Radiocephalic wrist arteriovenous fistula; Meta-analysis; Patency; Primary failure; Vascular access;
Hemodialysis.Introduction
Use of the radiocephalic arteriovenous fistula
(RCAVF) as an autologous vascular access for hemo-
dialysis dates back to the mid 1960s.1 Once estab-
lished, it has the advantage of good long-term
survival, and a low complication rate. Therefore, the
RCAVF is considered the optimal first choice for an
autologous hemodialysis fistula. However, the RCAVF
suffers from a high incidence of primary failure, due to
early thrombosis or failure to mature. Estimates of
primary failure, primary patency and secondarying author. Patrick P. G. M. Rooijens, Department of
ical Center Rijnmond Zuid, Location Clara, Olympia-
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that variability is the lack of precision in individual
studies.
In the present study, we aggregated primary failure
rates and primary and secondary patency data at 1
year of follow-up from various publications consider-
ing RCAVFs for hemodialysis, with the primary
objective of improving the precision of the estimates
of these parameters. The information derived will be
incorporated in a future decision model, we are
developing, to compare effects of various treatment
strategies for patients who need a vascular access for
hemodialysis. In addition to improving the precision,
a meta-analysis offers the opportunity to explore
questions that could not be answered by the original
studies by determining the effect of particular study
characteristics on the overall results. In the presentEur J Vasc Endovasc Surg 28, 583–589 (2004)
doi:10.1016/j.ejvs.2004.08.014, available online at http://www.sciencedirect.com onved.
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characteristics, including study year, gender and age,
on outcome.MethodsData sources and data extraction
A Medline search was performed of the English
language medical literature between January 1970
and October 2002. Key words that were searched
included radiocephalic fistula, arteriovenous shunt, Bres-
cia-Cimino fistula and patency. This electronic database
search was supplemented by manual search of
bibliographic reference lists in review articles and
original articles.
Studies that reported patency or primary failure
data of RCAVFs were included if: (1) the patient and
study characteristics were reported in sufficient detail
to allow for adjustment for the case mix and the
reporting methods in the analysis and (2) if the RCAVF
was created at the wrist. In instances in which more
than one publication from the same institution was
available, we included only the most recent publi-
cation from that institution, unless evidence was
available that the patient population did not overlap.
Because there are only a few prospective studies,2–9 we
also included retrospective studies in this meta-
analysis.10–39 Studies with insufficient information on
the location of the constructed autogenous arteriove-
nous fistula were excluded. Also publications were
excluded if the arteriovenous fistula was created in the
anatomical snuff box, upper arm or in the antecubital
fossa. In many of the studies that were included, the
results of the RCAVFs were reported together with
those of other types of autogenous arteriovenous
fistulas. Only when it was possible to separate the
results of the RCAVFs from those of the other types
these studies were included.
The methodological quality of included trials was
assessed independently by two reviewers, which
resolved any discrepancies by discussion and
consensus.
Nine prospective studies and 37 retrospective
studies were identified as possible candidates for this
meta-analysis. One prospective study and seven
retrospective studies were excluded, so that eight
prospective and 30 retrospective studies were
included in this meta-analysis.
A standard form was used to extract the data from
the articles, including characteristics of study design,
reporting methods, study population, patency data.Eur J Vasc Endovasc Surg Vol 28, December 2004We repeated the analysis for subgroups defined by
characteristics that might be of additional influence on
the primary failure and patency rates. For example, we
examined whether patency rates reported in studies,
which were performed before 1981, differ from
studies reported from 1981 up to 1991 or differ from
studies started after 1991. Other characteristics that
were examined in subgroup analyses include the
average age of the study population (%50 years
versusO50 years) and the percentage of women in
the study (%40 versusO40%). Both cut-off points are
median values of all studies combined.Outcome measures
The primary outcome measures were primary failure,
primary patency and secondary patency at 1 year of
follow-up. For the purpose of this analysis, primary
patency was defined as the interval from the time of
RCAVF creation until any intervention designed to
maintain or re-establish patency, fistula thrombosis, or
the time of measurement of patency. Secondary
patency was defined as the interval from the time of
RCAVF creation until access abandonment, thrombo-
sis, or the time of patency measurement including
intervening manipulations (surgical or endovascular
interventions) designed to re-establish functionality in
thrombosed access.40 Primary failure was defined as
fistula thrombosis, or failure to mature resulting in
inadequate functioning for hemodialysis at 6 weeks.Data analysis
Primary failure, primary and secondary patency rates
were analysed using the standardmixed effects model,
which allows for true variability between the studies.41
The estimated percentages and standard errors were
transformed to the logit scale, then the analysis was
carried out using SAS Proc Mixed,42 before retrans-
formation of data. The method allowed the specifica-
tion of covariates (meta-regression) in order to search
for the effect of possible explanatory variables. To
assess publication bias, funnel plots were derived,
accompanied by the linear regression test on sym-
metry.43 Throughout this report, two sided p-values are
reported, except for between study variances. A p-value
of!0.05 was considered to be statistically significant.Results
Nine prospective studies and 37 retrospective studies
were identified as possible candidates for this meta-
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eight prospective and 30 retrospective studies
remained. Patient characteristics of the included
prospective studies, ordered by calendar year, in
which the study started and finished, are given in
Table 1.
During the search for candidate studies for this
meta-analysis, we noticed that most studies, which
report on patency rates of RCAVFs, were retrospective.
Therefore, these studies were included in the analysis
separately, and in a subgroup analysis, we carefully
examined whether their results differed from the
prospective group. Patient characteristics of the retro-
spective studies, ordered by calendar year, in which
the study started and finished, are given in Table 2.
Primary failure rates and the primary and second-
ary patency rates at 1 year as reported in the
prospective studies are presented in Table 3. In all
prospective studies, a primary failure rate was
reported. Only one study reported a secondary
patency rate at 1 year, and another study also reported
a primary patency rate at 1 year. Two studies reported
both primary and secondary patency rates. Primary
failure rates differ significantly among these studies,
from Wetzig et al. reported a low primary failure rate
of 9.4%3 to Dixon et al. reported a very high primary
failure rate of 31.5%.5
Primary failure rates and the primary and second-
ary patency rates at 1 year from the various retro-
spective studies are reported in Table 4. In all but six
retrospective studies, primary failure rate was
reported. Four studies reported also primary patency
at 1 year and 11 studies reported also secondary
patency at 1 year. Only in two studies, both primary
and secondary patency at 1 year was reported.
In all eight prospective studies, and in 30 retro-
spective studies a primary failure rate was reported.
The estimated mean primary failure rate, based on the
data from the prospective studies, does not differ
statistically from that based on the retrospective
studies (16.9 versus 14.7%; pZ0.51). Therefore, weTable 1. Prospective studies regarding the outcome of RCAVFs for h
Author Study years Number of
patients
Number o
RCAVFs
Reilly et al.2 1976–1981 145 145
Wetzig et al.3 1979–1983 85 100
Wedgwood et
al.4
1981–1983 71 71
Dixon et al.5 1992–1998 73 73
Golledge et al.6 1993–1996 107 107
Malovrh7 1993–1997 116 116
Lin et al.8 1994–1995 176 176
Wong et al.9 1996 60 60pooled the data of the 38 studies, and the overall mean
primary failure rate was estimated as 15.3% (95% CI:
12.7–18.3%). There was very significant (p!0.0001)
heterogeneity between the studies, the range covering
95% of the study specific primary failure rate was
estimated as 6–34%.
The estimated primary patency rate at 1 year, based
on the retrospective studies, did not differ significantly
from that based on the data from the retrospective
studies (64.6 versus 61.5%; pZ0.73). The pooled
primary patency rate at 1 year based on the retro-
spective studies together with the prospective studies
was 62.5% (95% CI: 54.0–70.3%). Again the between
study heterogeneity was very significant (p!0.0001),
resulting in an estimated 95% range for the study
specific primary failure of 39–82%. Further, no
statistically significant difference was found between
the estimated secondary patency at 1 year based on the
prospective studies and that based on the retrospective
studies (68.5 versus 65.5%; pZ0.75). The pooled
estimated secondary patency at 1 year was 66.0%
(95% CI: 58.2–73.0%). The between study heterogen-
eity was very significant (p!0.0001), resulting in an
estimated 95% range for the study specific primary
failure of 36–87%.
Several subgroup analyses were performed. The
pooled results from the studies that included 40% or
fewer women were very similar to those from studies
with more than 40% women. The estimated primary
failure rate was 16.3 versus 15.9% (pZ0.09). Also the
estimated primary patency rate at 1 year (53.1 versus
69.1%; pZ0.07) and the estimated secondary patency
rate at 1 year (60.9 versus 64.8%; pZ0.66) did not differ
significantly between these two groups. The median
age of patients in all studies was 50 years. Therefore,
we investigated in a subgroup analysis if there was a
difference in primary failure rate and in patency rates
between the studies with a mean age of%50 years and
the studies with a mean age of O50 years. The
estimated primary failure rate among studies with a
mean age above 50 years was higher than for studiesemodialysis
f Male % Mean age (years) Age range
(years)
– – –
48 50.5 16–69
68 – –
82 51.6 –
68 63 –
47 51.4 15–81
45 57.8 20–86
62 58.4 17–77
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Table 2. Retrospective studies regarding the outcome of RCAVFs for hemodialysis
Author Study years Number of
patients
Number of
RCAVFs
Male % Mean age (years) Age range
(years)
Cohen et al.10 1966–1967 19 22 59 – 18–58
Ro¨hl et al.11 1966–1967 30 30 – – –
Kinnaert et al.12 1966–1975 202 202 62 – 16–69*
Tellis et al.13 1968–1971 59 59 59 – 14–55
Zerbino et al.14 1968–1974 160 160 99* – 19–77*
Thompson et
al.15
1970–1972 77 77 – – –
Cheek et al.16 1970–1973 84 84 – – –
Lindfors et al.17 1970–1973 45 45 67 42 18–67
Paruk et al.18 1971–1974 108 108 – – –
Tordoir et al.19 1971–1981 114 129 47 48.5 16–75
Burger et al.20 1971–1991 208 208 56* 46* 7–80*
Thomsen et al.21 1972–1978 191 191 56 49.1 7–74
Alm et al.22 1972–1974 67 67 48 48 12–67
Rohr et al.23 1973–1976 126 126 – 49* 14–82
Fernstro¨m et al.24 1975–1985 71 83 73 50 22–73
Kherlakian et
al.25
1977–1983 106 106 61 50 17–80
Simoni et al.26 1979–1989 248 248 54 53 19–83
Enzler et al.27 1980–1992 412 412 55* 43.9* 7–81*
Cassioumis et
al.28
1981–1992 173 173 – 55* 13–85*
Al-Mohoya et
al.29
1983–1988 112 112 60 – 13–75
Sparks et al.30 1983–1993 147 147 58* 53.8* 18–79*
Nazzal et al.31 1988–1989 85 85 61* 37* 7–70*
Leapman et al.32 1989–1994 144 150 73 50.1 19.2–87.5
Prischl et al.33 1989–1994 123 123 63* 54.2* 17–85*
Miller et al.34 1990–1994 41 41 45* 64.4* 33–90*
Bender et al.35 1993 56 56 56* 62* 7–83*
Lin et al.36 1994–1995 126 126 44 – 20–83
Zeebregts et al.37 1995–1999 150 153 63 56 17–80
Ascher et al.38 1996–1999 47 47 54* 69* 28–95*
Hingorani et al.39 1997–2001 206 206 – 68* 29–94*
* Based on all patients reported in the study, including patients with other procedures.
P. P. G. M. Rooijens et al.586with a mean age of 50 or less, but this difference was
not significant (15.5 versus 19.7%; pZ0.25). Also the
estimated primary patency rate at 1 year (59.4 versus
64.9%; pZ0.50) and the estimated secondary patency
rate at 1 year (66.4 versus 65.8%; pZ0.94) were not
different according to the age grouping. Finally a
subgroup analysis was performed concerning publi-
cation period. We divided the studies in three different
groups; studies performed before 1981, between 1981
and 1991, and performed after 1991. There were higher
estimated primary failure rate for studies performedTable 3. Primary failure rates and primary and secondary patency ra
Author Primary failure rate (%)
Reilly et al.2 11
Wetzig et al.3 9.4
Wedgwood et al.4 9.9
Dixon et al.5 31.5
Golledge et al.6 18
Malovrh7 19.8
Lin et al.8 13.6
Wong et al.9 29.6
Eur J Vasc Endovasc Surg Vol 28, December 2004after 1991, however, this difference was not significant
(13.5 versus 13.0 versus 18.0%; pZ0.14). The estimated
primary patency rate at 1 year (60.0% versus 62.7
versus 62.9%; pZ0.85) and the estimated secondary
patency rate at 1 year (55.7 versus 66.8 versus 67.7%;
pZ0.62) did not differ significantly between these two
groups.
No indication for publication bias in the primary
and secondary patency rates was observed. However,
there was a clear indication of publication bias for the
primary failure rates (pZ0.001) (Fig. 1). Points in thetes at 1 year as reported in the prospective studies
Primary patency rate at 1 year
(%)
Secondary patency rate at 1
year (%)
– 80
78 –
– –
44 52
69 70
– –
– –
– –
Table 4. Primary failure rates and primary and secondary patency rates at 1 year as reported in the retrospective studies
Author Primary failure rate (%) Primary patency rate at 1 year
(%)
Secondary patency rate at 1
year (%)
Cohen et al.10 13.6 – –
Ro¨hl et al.11 10 – –
Kinnaert et al.12 8.6 – –
Tellis et al.13 23.7 – 32.2
Zerbino et al.14 8.8 – –
Thompson et al.15 13.0 – –
Cheek et al.16 3.6 – –
Lindfors et al.17 15.6 – –
Paruk et al.18 15.7 – 75.9
Tordoir et al.19 10 – 80*
Burger et al.20 6.3 53 79
Thomsen et al.21 26 – 37
Alm et al.22 29.9 – –
Rohr et al.23 – 60* –
Fernstro¨m et al.24 29 45* 55*
Kherlakian et al.25 12 – 71
Simoni et al.26 – 75.5 –
Enzler et al.27 – – 74
Cassioumis et al.28 – – 79.1
Al-Mohaya et al.29 2.7 – –
Sparks et al.30 12.2 – –
Nazzal et al.31 – – 72
Leapman et al.32 13 – 56
Prischl et al.33 22.8 – 48
Miller et al.34 12.2 – –
Bender et al.35 9 – 76
Lin et al.36 23.8 – –
Zeebregts et al.37 27.5 55* –
Ascher et al.38 25 – –
Hingorani et al.39 – 75 –
* Data taken from figure.
Radiocephalic Arteriovenous Fistula: A Meta-analysis 587lower region of the plot have low precision and
correspond to small studies, and the variability
between studies is, therefore, larger than in the
upper region where the spread is smaller. If there is
no publication bias, the scatter should be symmetric
around the vertical line, independent of the precision.Fig. 1. Funnel plot indicating publication bias for primary
failure rates. The vertical reference line denotes the esti-
mated overall log odds.It is obvious that symmetry is violated. There should
be more small studies with large primary failure rates.
Therefore, small studies with worse primary failure
rates are underrepresented.Discussion
The aim of this study was to aggregate primary
patency, secondary patency and primary failure data
from multiple sources, representing more than three
decades of experience with the use of RCAVFs for
hemodialysis across the world. The meta-analysis
technique that we used allowed quantification of the
variability between studies. A huge heterogeneity
between studies was found in primary failure rates,
primary patency and secondary patency. There are
many potential causes of heterogeneity. An important
(partly) explanation might be the heterogeneity
between studies in the definitions of primary failure
and primary/secondary patency. Only a few authors
provided an explicit definition of the patency criterion
they used. When criteria were specified, many
different definitions were used. A very minor part ofEur J Vasc Endovasc Surg Vol 28, December 2004
P. P. G. M. Rooijens et al.588the heterogeneity might be related to the fact that in
some studies the patency data were given in the text
but presented in patency curves in figures. In some
instances, this allowed subjective interpretations of
these data, which may have resulted in larger
variability. However, the patency data were derived
independently by two different investigators, and did
not differ markedly.
The effect of sex on primary patency, secondary
patency and primary failure rates has been examined
in many studies.6,33,44 For example, Allon et al. found
that female sex was the only independent predictor of
decreased likelihood of fistula maturation.44 Colledge
et al. reported results from 107 patients (73 men, 43
women) with a first RCAVF; they found that fistula
failure was more common in women and primary and
secondary patency were better in men.6 In contrast,
Prischl et al. found no significant differences in access
survival between 80 men and 43 women on hemodia-
lysis with a first RCAVF.33 The different findings of
these studies, perhaps can be explained by the small
sample sizes and the fact that the populations were
derived from single centres. In the present study, no
significant relation was found between the gender
ratio and primary patency, secondary patency or
primary failure rates. With regard to age and access
patency several reports have failed to find any
association between age and access complications,45–
47 although others reported a significant effect of age
appearing after 6 months of follow-up. In this meta-
analysis, we found no relation between age and
primary or, secondary patency and primary failure
rates.
Finally our subgroup analysis showed a tendency
towards a higher primary failure rate of fistulas
constructed after 1991, however, this difference was
not significant. Possible explanations were that the
mean age of this subgroup was higher than in the
other two groups, and the more liberal selection
criteria for creation of a RCAVF, in recent years. In
addition, the chronic dialysis population is more likely
to have diabetes with various co-morbidities, includ-
ing peripheral arterial obstructive disease and coron-
ary artery sclerosis. Many of these patients appear to
have poor vessels for construction of autogenous
fistulas. Further, the Dialysis Outcome Quality Initiat-
ive (DOQI) published by the National Kidney Foun-
dation in 1997 advocated intensive efforts to increase
the use of RCAVF among these difficult dialysis
patients. There are two possible explanations for the
fact that there is no decrease in RCAVF patency over
the years. The first explanation is that co-morbidity,
like diabetes, has no significant influence on fistula
patency. This explanation is supported by severalEur J Vasc Endovasc Surg Vol 28, December 2004studies, in which no difference in fistula maturation
rates among diabetic and non-diabetic patients were
found.44,45,48 The other possible explanation is the
increased recognition of adequate pre-operative vessel
mapping and the value of fistula surveillance and
elective intervention with percutaneous angioplasty of
stenosed AVFs. However, as a result of this pre-
operative vessel mapping, one could expect a decrease
of primary failure rates and an increase of RCAVF
patency rates.
This study showed that differences in primary
failure, primary patency and secondary patency
cannot be attributed to patient demographics, such
as sex and age. Therefore, other factors must be taking
into account, such as vessel diameter and quality. In a
report of surgically created AVFs, Reilly et al. found
that vein size was a significant predictor of subsequent
fistula survival, while sex was not.2 A more recent
study also found that vessel size predicted fistula
failure in the first 3 months after surgery.9Conclusion
The current analysis aggregates primary failure and
primary and secondary 1-year patency rates from
multiple studies regarding autogenous wrist RCAVFs
for hemodialysis. The analysis showed a pooled
estimated primary failure rate of 15.3%. In addition
the pooled estimated primary and secondary patency
rates of 62.5 and 66.0%, respectively, were calculated.
Although, the autogenous RCAVF is considered to
be the primary choice for vascular access, it appears to
have a high primary failure rate and only moderate
patency rates at 1 year of follow-up.References
1 Brescia MJ, Cimino JE, Appel K, Hurwich BJ. Chronic
hemodialysis using venipuncture and a surgically created
arteriovenous fistula. N Engl J Med 1966;275:1089–1092.
2 Reilly DT, Wood RFM, Bell PRF. Prospective study of dialysis
fistulas: problem patients and their treatment. Br J Surg 1982;
69:549–553.
3 Wetzig GA, Gough IR, Furnival CM. One hundred cases of
arteriovenous fistula for haemodialysis access: the effect of
cigarette smoking on patency. Aust N Z J Surg 1985;55:551–554.
4 Wedgwood KR,Wiggins PA,Guillou PJ. A prospective study of
end-to-side vs. side-to-side arteriovenous fistulas for haemodia-
lysis. Br J Surg 1984;71:640–642.
5 Dixon BS, Novak L, Fangman J. Hemodialysis vascular access
survival: upper-arm native arteriovenous fistula. Am J Kidney Dis
2002;39:92–101.
6 Golledge J, Smith CJ, Farrington K, ThompsonHH. Outcome
of primary radiocephalic fistula for haemodialysis. Br J Surg 1999;
86:211–216.
Radiocephalic Arteriovenous Fistula: A Meta-analysis 5897 Malovrh M. Native arteriovenous fistula: preoperative evalu-
ation. Am J Kidney Dis 2002;39:1218–1225.
8 Lin SH, Huang CH, Chen HS, Hsu WA, Yen CJ, Yen TS. Effects
of age and diabetes on blood flow rate and primary outcome of
newly created hemodialysis arteriovenous fistula. Am J Nephrol
1998;18:96–100.
9 Wong V,Ward R, Taylor J, Selvakumar S, How TV, Bakran A.
Factors associated with early failure of arteriovenous fistulae for
haemodialysis access. Eur J Endovasc Surg 1996;12:207–213.
10 Cohen S, Lidksy I, Kest L, Kastagir B, Vertes V. Experience
with arteriovenous fistulas. Trans Am Soc Artif Int Organs 1968;
14:421–425.
11 Ro¨hl L, FranzHE,Mo¨hringK, Ritz E, Schu¨lerHW,UhseHG,
Ziegler M. Direct arteriovenous fistula for hemodialysis. Scand
J Urol Nephrol 1968;2:191–195.
12 Kinnaert P, Vereerstraeten P, Toussaint C, Van
Geertruyden J. Nine years’ experience with internal arteriove-
nous fistulas for haemodialysis: a study of some factors
influencing the results. Br J Surg 1977;64:242–246.
13 Tellis VA, Veith FJ, Soberman RJ, Freed SZ, Gliedman ML.
Internal arteriovenous fistula for hemodialysis. Surg Gynecol
Obstet 1971;132:866–870.
14 Zerbino VR, Tice DA, Katz LA, Nidus BD. A 6 year clinical
experience with arteriovenous fistulas and bypasses for hemo-
dialysis. Surgery 1974;76:1018–1023.
15 Thompson BW, Barbour G, Bissett J. Internal arteriovenous
fistula for hemodialysis. Am J Surg 1972;124:785–788.
16 Cheek RC,Messina JJ, Acchiardo SR, Britt LG. Arteriovenous
fistulas for hemodialysis: experience with 100 cases. Am Surg
1976;42:386–389.
17 Lindfors O, Paldanius R. Experience with arteriovenous
fistulas (Cimino) in chronic hemodialysis. Scand J Urol Nephrol
1976;10:80–83.
18 Paruk S,KoenigM, Levitt S,HardyMA. Arteriovenous fistulas
for hemodialysis in 100 consecutive patients. Am J Surg 1976;
131:552–555.
19 Tordoir JHM, Kwan TS, Herman JMMPH, Carol EJ,
Jakimowicz JJ. Primary and secondary access surgery for
haemodialysis with the Brescia-Cimino fistula and the polytetra-
fluorethylene (PTFE) graft. Neth J Surg 1983;35:8–12.
20 Burger H, Kluchert BA, Kootstra G, Kitslaar PJ,
Ubbink DTH. Survival of arteriovenous fistulas and shunts for
haemodialysis. Eur J Surg 1995;161:327–334.
21 ThomsenMB, Deurell SI, Elfstro¨m J, Alm A. What causes the
failure in surgically constructed arteriovenous fistulas. Acta Chir
Scand 1983;149:371–376.
22 Alm A, Lundberg M. Clinical experience with therapeutic
arteriovenous fistulae. Scand J Urol Nephrol 1977;11:53–57.
23 Rohr MS, Browder W, Frentz GD, McDonald JC. Arteriove-
nous fistulas for long-term dialysis. Factors that influence fistula
survival. Arch Surg 1978;113:153–155.
24 Fernstro¨m A, Hylander B, Olofsson P, Swedenborg J. Long
and short term patency of radiocephaloc arteriovenous fistulas.
Acta Chir Scand 1988;154:257–259.
25 Kherlakian GM, Roedersheimer LR, Arbaugh JJ,
Newmark KJ, King LR. Comparison of autogenous fistula
versus expanded polytetrafluorethylene graft fistula for angioac-
cess in hemodialysis. Am J Surg 1986;152:238–243.
26 Simoni G, Bonalumi U, Civalleri D, Decian F, Bartoli FG.
End-to-end arteriovenous fistula for chronic haemodialysis: 11
years’ experience. Cardiovasc Surg 1994;2:63–66.
27 Enzler MA, Rajmon T, Lachat M, Largiader F. Long-term
function of vascular access for hemodialysis. Clin Transplant 1996;
10:511–515.
28 Cassioumis D, Fatouros MS, Siamopoulos KC,
Giannoukas AD. Short- an long-term evaluation of arteriove-
nous fistulas for chronic hemodialysis.Microsurgery 1992;13:236–
237.
29 Al-Mohaya S, Al-Awami SM, Sadat-Ali M. Arteriovenous
fistula for hemodialysis a report of 112 consecutive cases. Indian
J Med Sci 1990;44:33–36.30 Sparks SR, VanderLinden JL, Gnanadev DA, Smith JW,
Bunt TJ. Superior patency of perforating antecubital vein
arteriovenous fistulae for hemodialysis. Ann Vasc Surg 1997;
11:165–167.
31 Nazzal MMS, Neglen P, Naseem J, Christenson JT, al-
Hassan HK. The brachiocephalic fistula: a successful secondary
vascular access procedure. Vasa 1990;19:326–329.
32 Leapman SB, Boyle M, Pescovitz MD, Milgrom ML,
Jindal RM, Filo RS. The arteriovenous fistula for hemodialysis
access: fold standard of archaic relic? Am Surg 1996;62:652–656.
33 Prischl FC, Kirchgatterer A, Brandsta¨tter E, Wallner M,
Baldinger C, Roithinger FX, Kramar R. Parameters of
Prognostic Relevance to the patency of vascular access in
hemodialysis patients. J Am Soc Nephrol 1995;6:1613–1618.
34 Miller A, Ho¨lzenbein TJ, Gottlieb MN, Sacks BA, Lavin PT,
Goodman WS, Gupta SK. Strategies to increase the use of
autogenous arteriovenous fistula in end-stage renal disease. Ann
Vasc Surg 1997;11:397–405.
35 BenderMHM, Bruyninckx CMA, Gerlag PGG. The brachioce-
phalic elbow fistula: a useful alternative angioaccess for
permanent hemodialysis. J Vasc Surg 1994;20:808–813.
36 Lin SL, ChenHS,Huang CH, Yen TS. Predicting the outcome of
hemodialysis arteriovenous fistulae using duplex utrasonogra-
phy. J Formos Med Assoc 1997;96:864–868.
37 Zeebregts C, van den Dungen J, Bolt A, Franssen C,
Verhoeven E, van Schilfgaarde R. Factors predictive of failure
of Brescia-Cimino arteriovenous fistulas. Eur J Surg 2002;168:29–
36.
38 Ascher E, Gade P, Hingorani A, Mazzariol F, Gunduz Y,
FoderaM, YorkovichW. Changes in the practice of angioaccess
surgery: impact of dialysis outcome and quality initiative
recommendations. J Vasc Surg 2000;31:84–92.
39 Hingorani A, Ascher E, Kallakuri S, Greenberg S,
Khanimov Y. Impact of reintervention for failing upper-
extremity arteriovenous autogenous access for hemodialysis.
J Vasc Surg 2001;34:1004–1009.
40 Sidawy AN, Gray R, Besarad A, HenryM, Ascher E, SilvaM,
MillerA, Scher L, Trerotola S,Gregory RT, Rutherford RB,
Kent KG. Recommended standards for reports dealing with
arteriovenous hemodialysis accesses. J Vasc Surg 2002;35:603–610.
41 DerSimonian R, LairdN.Meta-analysis in clinical trials. Control
Clin Trials 1986;7(3):177–188.
42 Houwelingen van JC, Arends LR, Stijnen T. Advanced
methods in meta-analysis: multivariate approach and meta-
regression. Stat Med 2002;21(4):589–624.
43 Egger M, Davey Smith G, Scheinder M, Minder C. Bias in
meta-analysis detected by a simple, graphical test. Br Med J 1997;
315:629–634.
44 Allon M, Lockhart ME, Lilly RZ, Gallichio MH, Young CJ,
Barker J, Deierhoi MH, Robbin ML. Effect of preoperative
sonographic mapping on vascular access outcomes in hemodia-
lysis patients. Kidney Int 2001;2013–2020.
45 Zibari GB, Rohr MS, Landreneau MD, Bridges RM,
DeVaut GA, Petty FH, Costley KJ, Brown ST, McDonald JC.
Complications from permanent hemodialysis vascular access.
Surgery 1988;140:681–686.
46 Churchill DN, Taylor DW, Cook RJ, LaPlante P, Barre P,
Cartier P, Fay WP, Goldstein MB, Jindal K, Mandin H.
Canadian hemodialysis morbidity study. Am J Kidney Dis 1992;
19:214–234.
47 RoccoMV, Bleyer AJ, Burkart JM. Utilization of inpatient and
outpatient resources for the management of hemodialysis access
complications. Am J Kidney Dis 1996;28:250–256.
48 SedlacekM, Teodorescu V, FalkA, Vassalotti JA, Uribarri J.
Hemodialysis access placement with preoperative noninvasive
vascular mapping: comparison between patients with and
without diabetes. Am J Kidney Dis 2001;38:560–564.
Accepted 31 August 2004
Available online 2 October 2004Eur J Vasc Endovasc Surg Vol 28, December 2004
